We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 8, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. (MRK - Free Report) , ConocoPhillips (COP - Free Report) , Adobe Inc. (ADBE - Free Report) , Intercontinental Exchange, Inc. (ICE - Free Report) and Monster Beverage Corp. (MNST - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Merck, ConocoPhillips and Adobe
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., ConocoPhillips and Adobe Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+20.0% vs. +7.6%). The company’s drugs like Keytruda, Gardasil vaccine and Bridion have been driving sales. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.
Animal health and vaccine products are core growth drivers. Its new COVID oral antiviral pill, Lagevrio, has become a key top-line driver in 2022. However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line.
There are concerns about Merck’s ability to grow its non-oncology business ahead of Keytruda’s loss of exclusivity later in the decade. Merck’s shares have outperformed the industry this year so far.
Shares of ConocoPhillips have outperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (+74.2% vs. +72.0%). The company holds a bulk of acres in the unconventional plays of Eagle Ford shale, Permian Basin and Bakken shale. Significant opportunities are there for the firm in the Bakken Shale, where it owns about 750 undrilled locations that could provide access to huge reserves.
COP projects its 2022 production at 1.74 million barrels of oil equivalent per day (MMBoe/d), suggesting an increase from 1.6 MMBoe/d last year. COP’s balance sheet is significantly less leveraged than the industry it belongs to. Also, it approved a $20-billion increase in the existing share repurchase program to $45 billion.
However, COP is highly exposed to oil price fluctuations, which makes things challenging for the company. Also, it has been generating lower dividend yield than the industry over the past few years. As such, the stock warrants a cautious stance.
Shares of Adobe have underperformed the Zacks Computer - Software industry over the past year (-57.1% vs. -37.2%). The company is facing headwinds for the Digital Media segment due to the ongoing tensions between Russia and Ukraine conflict. Nevertheless, Adobe is benefiting from strong demand for its cloud products.
The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are helping it drive top-line growth. Rising subscription revenues and solid momentum across the mobile apps remain major positives.
Growth in emerging markets, robust online video creation demand, strong Acrobat adoption and improving average revenue per user remain tailwinds. We remain optimistic about Adobe’s market position, compelling product lines, persistent innovation and solid adoption of Creative Cloud and Adobe marketing cloud.
Other noteworthy reports we are featuring today include Intercontinental Exchange, Inc. and Monster Beverage Corp.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Zacks Analyst Blog Highlights Merck, ConocoPhillips, Adobe, Intercontinental Exchange and Monster Beverage
For Immediate Release
Chicago, IL – November 8, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck & Co., Inc. (MRK - Free Report) , ConocoPhillips (COP - Free Report) , Adobe Inc. (ADBE - Free Report) , Intercontinental Exchange, Inc. (ICE - Free Report) and Monster Beverage Corp. (MNST - Free Report) .
Here are highlights from Monday’s Analyst Blog:
Top Research Reports for Merck, ConocoPhillips and Adobe
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc., ConocoPhillips and Adobe Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Merck’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+20.0% vs. +7.6%). The company’s drugs like Keytruda, Gardasil vaccine and Bridion have been driving sales. With continued label expansion into new indications & early-stage settings, Keytruda is expected to remain a key top-line driver.
Animal health and vaccine products are core growth drivers. Its new COVID oral antiviral pill, Lagevrio, has become a key top-line driver in 2022. However, generic competition for several drugs and rising competitive pressure, mainly on the diabetes franchise, will continue to be overhangs on the top line.
There are concerns about Merck’s ability to grow its non-oncology business ahead of Keytruda’s loss of exclusivity later in the decade. Merck’s shares have outperformed the industry this year so far.
(You can read the full research report on Merck here >>>)
Shares of ConocoPhillips have outperformed the Zacks Oil and Gas - Integrated - United States industry over the past year (+74.2% vs. +72.0%). The company holds a bulk of acres in the unconventional plays of Eagle Ford shale, Permian Basin and Bakken shale. Significant opportunities are there for the firm in the Bakken Shale, where it owns about 750 undrilled locations that could provide access to huge reserves.
COP projects its 2022 production at 1.74 million barrels of oil equivalent per day (MMBoe/d), suggesting an increase from 1.6 MMBoe/d last year. COP’s balance sheet is significantly less leveraged than the industry it belongs to. Also, it approved a $20-billion increase in the existing share repurchase program to $45 billion.
However, COP is highly exposed to oil price fluctuations, which makes things challenging for the company. Also, it has been generating lower dividend yield than the industry over the past few years. As such, the stock warrants a cautious stance.
(You can read the full research report on ConocoPhillips here >>>)
Shares of Adobe have underperformed the Zacks Computer - Software industry over the past year (-57.1% vs. -37.2%). The company is facing headwinds for the Digital Media segment due to the ongoing tensions between Russia and Ukraine conflict. Nevertheless, Adobe is benefiting from strong demand for its cloud products.
The company’s Creative Cloud, Document Cloud and Adobe Experience Cloud products are helping it drive top-line growth. Rising subscription revenues and solid momentum across the mobile apps remain major positives.
Growth in emerging markets, robust online video creation demand, strong Acrobat adoption and improving average revenue per user remain tailwinds. We remain optimistic about Adobe’s market position, compelling product lines, persistent innovation and solid adoption of Creative Cloud and Adobe marketing cloud.
(You can read the full research report on Adobe here >>>)
Other noteworthy reports we are featuring today include Intercontinental Exchange, Inc. and Monster Beverage Corp.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.